Novel blood marker shown to predict the incidence and severity of coronary artery disease

NEW ORLEANS, LA, Nov. 14, 2000, 4 pm EST Scientists from San Diego State University in collaboration with the Naval Medical Center of San Diego today announced study results that could lead to a simple, inexpensive blood test for predicting the presence and extent of coronary artery disease (CAD). The results were presented during the American Heart Association 73rd Scientific Sessions in New Orleans.

The MIRF (Myocardial Ischemia Rating Function) Trial was a double-blinded study of over 300 patients designed to test the utility of measuring serum sphingolipids (a type of lipids in the blood) as predictors of CAD and the resulting ischemia (reduced blood flow) it can cause in heart muscle.

In this study, sphingolipid levels were highly correlated with the incidence and severity of CAD as measured by angiography. Results from the clinical trial demonstrated that these novel ischemia markers were better predictors of CAD than all of the conventional risk factors such as age, gender, elevated cholesterol, and hypertension.

Disease predictability can be enhanced if the sphingolipid markers were combined with the strongest risk factors of age and gender to form the "MIRF" index. The relative risk of CAD was found to be more than 10 times higher in patients with high MIRF scores. Moreover, the MIRF index can predict the number of coronary blood vessels obstructed by CAD. Further, in high-risk hospitalized patients, the sphingolipid ischemia markers were shown to be a better predictor of CAD than age and gender combined.

"We conclude that the serum levels of sphingolipids are potentially strong and robust measures of CAD and may form the basis for a simple screening test to accurately determine the incidence and severity of cardiac ischemia," said Roger A. Sabbadini, Ph.D., professor of biology at San Diego State University and president of Medlyte Diagnostics, Inc. The research was supported by Medlyte Diagno

Contact: Leslie Anne Mogul
Medlyte Diagnostics, Inc.

Page: 1 2

Related biology news :

1. Novel IBD therapeutic approaches reported from Washington Univ., Barcelona, LSU at APS meeting
2. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
3. Novel approaches to current cellular therapies continue progress toward disease prevention
4. Novel therapies show promise against myeloid leukemia
5. Novel sensors help clear the air
6. Fox Chase Cancer Center study: Novel DNA-repair gene mutation can cause resistance to cancer drugs
7. Novel proteins designed that block inflammation regulator associated with rheumatoid arthritis
8. Novel therapeutic target identified in fight against Rheumatoid Arthritis
9. Novel bacterium detoxifies chlorinated pollutants
10. Novel flu vaccine shows promise in mice
11. Novel gene therapy on the horizon, says Brenner Childrens Hospital pediatrician

Post Your Comments:

(Date:7/31/2020)... ... July 30, 2020 , ... Justin Zamirowski ... with a near term focus on Type 2 diabetes and associated comorbidities. , ... multiple therapeutic areas and classes. As Chief Commercial Officer, Justin will lead ...
(Date:7/10/2020)... ... July 08, 2020 , ... Overcoming Comparability ... Regulation, An FDAnews Webinar, Wednesday, July 22, 2020 • 1:30 p.m.-3:00 p.m. EDT, ... is the most effective way to complete one? Will the study comply with ...
(Date:7/2/2020)... ... July 02, 2020 , ... ... publication detailing the use of its revolutionary NEXTGENPCR endpoint thermocycler to test ... 16 minutes. The article, titled "Ultra-fast one-step RT-PCR protocol for the detection ...
Breaking Biology News(10 mins):
(Date:9/3/2020)... ... 03, 2020 , ... The fifth annual AGBT Precision Health ... their latest research and technology in the areas of genomics, medicine, and health. ... therapeutic development, as well as the evolving view of genotype-phenotype interpretation from rare ...
(Date:9/1/2020)... ... September 01, 2020 , ... ... biotechnology, and diagnostics companies, has announced the placement of Julianne Averill , ... responsible for leading all financial operations and implementing key business strategies to accelerate ...
(Date:8/31/2020)... ... August 29, 2020 , ... DuPont ... capability in Wuxi, China. The new plant operation will provide the local animal ... technology. , “This facility will improve the flexibility of our offerings to ...
(Date:8/15/2020)... ... August 13, 2020 , ... True Terpenes , the leading ... Scientific Advisory Board (SAB) to research the medical potential of terpenes and the potential ... combined with terpenes. The board is focused on expanding the recently launched line of ...
Breaking Biology Technology:
Cached News: